GlassScriptPhysician profile
Bethany C Hahn
NPI 1952564700
$2,852.51
in general payments reported to CMS, 2019-2025
33 companies · $455 in 2025
The $455 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $105 · 2021: $204 · 2022: $412 · 2023: $571 · 2024: $709 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $764.35 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $315.77 | 2021-2025 | |
| Optumhealth Care Solutions, LLC | $260.07 | 2023-2025 | Vivify Health Care Team Portal 001, Eitan Medical, Vivify Health Care Team Portal |
| Astellas Pharma US INC | $194.16 | 2022-2025 | Veozah |
| Organon LLC | $133.93 | 2021-2025 | Nexplanon |
| Exeltis, USA INC. | $120.93 | 2019-2023 | Slynd |
| Biogen, INC. | $104.42 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $98.00 | 2021-2023 | Twirla |
| Roche Diagnostics Corporation | $64.11 | 2019 | |
| Amag Pharmaceuticals, INC. | $62.88 | 2019-2020 | |
| Therapeuticsmd, INC. | $61.93 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.58 | 2019-2023 | |
| Coopersurgical, INC. | $52.02 | 2019-2024 | Paragard T 380a |
| Allergan, INC. | $46.07 | 2019 | |
| Shield Therapeutics INC | $45.93 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $45.38 | 2022 | |
| Evofem Biosciences, INC. | $44.36 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $40.32 | 2023-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $38.35 | 2019-2024 | Gardasil 9, Gardasil |
| Boston Scientific Corporation | $33.52 | 2023 | |
| Smith+Nephew, INC. | $32.83 | 2022-2023 | Pico 7 |
| Hologic Sales and Service, LLC | $32.16 | 2019 | |
| Baxter Healthcare | $28.69 | 2024 | Perclot |
| Aspira Women'S Health INC | $27.04 | 2021-2024 | Ova1 |
| Mylan Pharmaceuticals INC. | $22.23 | 2022 | |
| Millicent US INC | $21.67 | 2024 | Intrarosa, Femring |
| Myovant Sciences INC. | $20.54 | 2021 | |
| Amgen INC. | $16.48 | 2020 | |
| Pfizer INC. | $15.78 | 2024 | |
| Northgate Technologies, INC. | $14.66 | 2023 | Stimsite (Nti) |
| Gynesonics, INC. | $14.03 | 2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Olympus America INC. | $13.32 | 2019 | |
| Lupin INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.